Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|March 14, 2007
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cellsAlan Pourpak, Terry H Landowski, Robert T DorrOncogene|October 25, 2003
Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell deathLori A Hazlehurst, Terry H Landowski, William S DaltonInvestigational New Drugs|September 17, 2013
The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancersTerry H Landowski, Betty K Samulitis, Robert T DorrJournal of Immunology (Baltimore, Md. : 1950)|February 23, 2002
Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell linesKenneth H Shain, Terry H Landowski, William S DaltonInvestigational New Drugs|July 9, 2008
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cellsBetty K Samulitis, Terry H Landowski, Robert T DorrLeukemia & Lymphoma|December 3, 2005
Correlates of imexon sensitivity in human multiple myeloma cell linesBetty K Samulitis, Terry H Landowski, Robert T DorrCancer Chemotherapy and Pharmacology|March 3, 2007
Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell linesJulie Scott, Robert T Dorr, Betty Samulitis, et al.Oncogene|April 30, 2003
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cellsTerry H Landowski, Nancy E Olashaw, Deepak Agrawal, et al.Blood|October 18, 2002
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanismYun Dai, Terry H Landowski, Steven T Rosen, et al.Cancer Chemotherapy and Pharmacology|March 27, 2010
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductaseNicholas O Roman, Betty K Samulitis, Lee Wisner, et al.Pageof 3